Short Interest in Nanovibronix, Inc. (NASDAQ:FEED) Increases By 1,387.8%

Nanovibronix, Inc. (NASDAQ:FEED) saw a significant increase in short interest in May. As of May 15th, there was short interest totaling 163,391 shares, an increase of 1,387.8% from the April 30th total of 10,982 shares. Approximately 2.7% of the shares of the company are short sold. Based on an average trading volume of 982,721 shares, the days-to-cover ratio is currently 0.2 days.

Analysts Set New Price Targets

FEED has been the subject of several recent research reports. Wall Street Zen upgraded Nanovibronix from a “strong sell” rating to a “sell” rating in a research report on Tuesday, April 28th. Weiss Ratings restated a “sell (e+)” rating on shares of Nanovibronix in a research report on Friday, April 24th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has a consensus rating of “Sell”.

Nanovibronix Stock Performance

Shares of FEED traded down $0.01 during trading hours on Wednesday, hitting $0.92. 101,504 shares of the stock were exchanged, compared to its average volume of 705,619. Nanovibronix has a 12-month low of $0.84 and a 12-month high of $17.40. The firm has a market capitalization of $5.60 million, a P/E ratio of -0.10 and a beta of 1.59. The stock has a 50-day moving average price of $1.49.

Nanovibronix (NASDAQ:FEED) last released its quarterly earnings data on Monday, May 18th. The company reported ($6.88) earnings per share for the quarter. The company had revenue of $0.65 million for the quarter. Nanovibronix had a negative return on equity of 54.25% and a negative net margin of 923.20%.

Nanovibronix Company Profile

Nanovibronix (NASDAQ: FEED) is a medical device company focused on the development and commercialization of non‑invasive therapeutic ultrasound technologies for clinical and consumer healthcare applications. The company’s product portfolio centers on wearable ultrasound devices designed to deliver low‑intensity acoustic energy to soft tissue with the objective of promoting wound healing and reducing pain. Nanovibronix positions its technology as an alternative or adjunct to conventional wound‑care and analgesic therapies, aiming to address chronic and acute conditions that are managed in both outpatient and home settings.

The company concentrates its commercial efforts on supplying hospitals, wound‑care clinics, long‑term care facilities and patients requiring home‑based therapies.